Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.

Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, Beal JC, Laux LC, De Boer LM, Wong MH, Lopez M, Devinsky O, Lyons PD, Zentil PP, Wechsler R; CBD EAP study group.

Epilepsia. 2018 Aug;59(8):1540-1548. doi: 10.1111/epi.14477. Epub 2018 Jul 12.

2.

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.

Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE1 Part A Study Group.

Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14.

3.

Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.

Wong MH, Xue A, Baxter RC, Pavlakis N, Smith RC.

Neoplasia. 2016 Jul;18(7):425-35. doi: 10.1016/j.neo.2016.06.001.

4.

Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET).

Wong MH, Chan DL, Lee A, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N.

PLoS One. 2016 Jun 30;11(6):e0158140. doi: 10.1371/journal.pone.0158140. eCollection 2016. Review.

5.

Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors.

Lee A, Chan DL, Wong MH, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N.

Neuroendocrinology. 2017;104(3):209-222. doi: 10.1159/000446115. Epub 2016 Apr 16. Review.

6.

A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas.

Xue A, Julovi SM, Hugh TJ, Samra JS, Wong MH, Gill AJ, Toon CW, Smith RC.

Pancreatology. 2015 Jul-Aug;15(4):397-404. doi: 10.1016/j.pan.2015.04.008. Epub 2015 May 10.

PMID:
26026767
7.

Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.

Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC.

Clin Cancer Res. 2014 Aug 1;20(15):4047-58. doi: 10.1158/1078-0432.CCR-13-3377. Epub 2014 Jun 3.

8.

Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice.

Li BT, Wong MH, Pavlakis N.

J Clin Med. 2014 Jan 9;3(1):1-24. doi: 10.3390/jcm3010001. Review.

9.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474. doi: 10.1002/14651858.CD003474.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Oct 30;10 :CD003474.

PMID:
22336790
10.

Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ.

Kurniawan ED, Rose A, Mou A, Buchanan M, Collins JP, Wong MH, Miller JA, Mann GB.

Arch Surg. 2010 Nov;145(11):1098-104. doi: 10.1001/archsurg.2010.243.

PMID:
21079099
11.

Predictors of surgical margin status in breast-conserving surgery within a breast screening program.

Kurniawan ED, Wong MH, Windle I, Rose A, Mou A, Buchanan M, Collins JP, Miller JA, Gruen RL, Mann GB.

Ann Surg Oncol. 2008 Sep;15(9):2542-9. doi: 10.1245/s10434-008-0054-4. Epub 2008 Jul 10.

PMID:
18618180

Supplemental Content

Loading ...
Support Center